Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor-dependent preservation of growth in the developing lung

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 310, Issue 11, 2016, Pages L1098-L1110

  Seedorf, Gregory ^a   Metoxen, Alexander J ^a   Rock, Robert ^a   Markham, Neil ^a   Ryan, Sharon ^a   Vu, Thiennu ^b   Abman, Steven H ^a  

^a CHILDREN S HOSPITAL COLORADO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bronchopulmonary dysplasia; Endothelial nitric oxide synthase; Hepatocyte growth factor; Lung development; Lung hypoplasia; Nitric oxide; Vascular endothelial growth factor

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; HEPATOCYTE GROWTH FACTOR ANTIBODY; JNJ 38877605; PROTEIN ANTIBODY; RECEPTOR BLOCKING AGENT; RECOMBINANT SCATTER FACTOR; RECOMBINANT VASCULOTROPIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SEMAXANIB; UNCLASSIFIED DRUG; VASCULOTROPIN; HGF PROTEIN, MOUSE; NOS3 PROTEIN, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; FEMALE; FETUS; FETUS LUNG; HYPEROXIA; IN VITRO STUDY; IN VIVO STUDY; LUNG DEVELOPMENT; LUNG STRUCTURE; MALE; MESENCHYME CELL; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; ANIMAL; C57BL MOUSE; CELL ADHESION; CELL CULTURE; CYTOLOGY; ENDOTHELIUM CELL; GENETICS; GROWTH, DEVELOPMENT AND AGING; KNOCKOUT MOUSE; LUNG; LUNG ALVEOLUS EPITHELIUM CELL; METABOLISM; PHYSIOLOGY; PULMONARY ARTERY; SHEEP; VASCULAR ENDOTHELIUM;

ALVEOLAR EPITHELIAL CELLS; ANIMALS; CELL ADHESION; CELLS, CULTURED; COCULTURE TECHNIQUES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HEPATOCYTE GROWTH FACTOR; LUNG; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE III; PULMONARY ARTERY; SHEEP; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84984608934     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00423.2015     Document Type: Article

References (59)

1. Abman SH. Bronchopulmonary Dysplasia. New York: Informa Healthcare, 2010, p. 17.
2. Abman SH. Impaired vascular endothelial growth factor signaling in the pathogenesis of neonatal pulmonary vascular disease. In: Membrane Receptors, Channels and Transporters in Pulmonary Circulation, edited by Yuan JXJ and Ward JPT. New York: Humana, 2010, p. 323-335.
3. Balasubramaniam V. Nitric oxide augments fetal pulmonary artery endothelial cell angiogenesis in vitro. Am J Physiol Lung Cell Mol Physiol 290: L1111-L1116, 2006.
4. Balasubramaniam V, Maxey A, Abman S. Inhaled nitric oxide reverses hypoxia induced lung hypoplasia in endothelial nitric oxide synthasedeficient mice. Chest 128: 613S-614S, 2005.
5. Balasubramaniam V, Maxey AM, Morgan DB, Markham NE, Abman SH. Inhaled NO restores lung structure in eNOS-deficient mice recovering from neonatal hypoxia. Am J Physiol Lung Cell Mol Physiol 291: L119-L127, 2006.
6. Balasubramaniam V, Ryan SL, Seedorf GJ, Roth EV, Heumann TR, Yoder MC, Ingram DA, Hogan CJ, Markham NE, Abman SH. Bone marrow derived angiogenic cells restore lung alveolar and vascular structure after neonatal hyperoxia in infant mice. Am J Physiol Lung Cell Mol Physiol 298: L315-L323, 2010.
7. Balasubramaniam V, Tang JR, Maxey A, Plopper CG, Abman SH. Mild hypoxia impairs alveolarization in the endothelial nitric oxide synthase-deficient mouse. Am J Physiol Lung Cell Mol Physiol 284: L964-L971, 2003.
8. Ballard RA, Truog WE, Cnaan A, Martin RJ, Ballard PL, Merrill JD, Walsh MC, Durand DJ, Maycock DE, Eichenwald EC, Null DR, Hudak ML, Puri AR, Golombek SG, Courtney SE, Stewart DL, Welty SE, Phibbs RH, Hibbs AM, Luan X, Wadlinger SR, Asselin JM, Coburn CE. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 355: 343-453, 2006.
9. Barrington KJ, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 12: CD000509, 2010.
10. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 164: 1971-1980, 2001.
11. Bland RD, Albertine KH, Carlton DP, MacRitchie AJ. Inhaled nitric oxide effects on lung structure and function in chronically ventilated preterm lambs. Am J Respir Crit Care Med 172: 899-906, 2005.
12. Brown KRS, England KM, Goss KL, Snyder JM, Acarregui MJ. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro. Am J Physiol Lung Cell Mol Physiol 281: L1001-L1010, 2001.
13. Cole FS, Alleyne C, Barks JD, Boyle RJ, Carroll JL, Dokken D, Edwards WH, Georgieff M, Gregory K, Johnston MV, Kramer M, Mitchell C, Neu J, Pursley DM, Robinson WM, Rowitch DH. NIH consensus development conference statement: inhaled nitric-oxide therapy for premature infants. Pediatrics 127: 363-369, 2011.
14. Cooney TP, Thurlbeck WM. The radial alveolar count method of Emery and Mithal: a reappraisal 2—intrauterine and early postnatal lung growth. Thorax 37: 580-583, 1982.
15. Fanaroff AA, Stoll BJ, Wright LL, Carlo WA, Ehrenkranz RA, Stark AR, Bauer CR, Donovan EF, Korones SB, Laptook AR, Lemons JA, Oh W, Papile LA, Shankaran S, Stevenson DK, Tyson JE, Poole WK. Trends in neonatal morbidity and mortality for very low birthweight infants. Am J Obstet Gynecol 196: 147.e1-e8, 2007.
16. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003.
17. Gerber HP, Hillan KJ, Ryan AM, Kowalski J, Keller GA, Rangell L, Wright BD, Radtke F, Aguet M, Ferrara N. VEGF is required for growth and survival in neonatal mice. Development 126: 1149-1159, 1999.
18. Grover TR, Parker TA, Zenge JP, Markham NE, Kinsella JP, Abman SH. Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 284: L508-L517, 2003.
19. Han RN, Babaei S, Robb M, Lee T, Ridsdale R, Ackerley C, Post M, Stewart DJ. Defective lung vascular development and fatal respiratory distress in endothelial NO synthase-deficient mice: a model of alveolar capillary dysplasia? Circ Res 94: 1115-1123, 2004.
20. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377: 239-242, 1995.
21. Ito Y, Correll K, Schiel JA, Finigan JH, Prekeris R, Mason RJ. Lung fibroblasts accelerate wound closure in human alveolar epithelial cells through hepatocyte growth factor/c-Met signaling. Am J Physiol Lung Cell Mol Physiol 307: L94-L105, 2014.
22. Ito Y, Correll K, Zemans RL, Leslie CC, Murphy RC, Mason RJ. Influenza induces IL-8 and GM-CSF secretion by human alveolar epithelial cells through HGF/c-Met and TGF-a/EGFR signaling. Am J Physiol Lung Cell Mol Physiol 308: L1178-L1188, 2015.
23. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, Abman SH. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 279: L600-L607, 2000.
24. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, Sekar KC, Bhutani VK, Gerdes JS, George TN, Southgate WM, Carriedo H, Couser RJ, Mammel MC, Hall DC, Pappagallo M, Sardesai S, Strain JD, Baier M, Abman SH. Early inhaled nitric oxide therapy in premature newborns with respirator failure. N Engl J Med 355: 354-364, 2006.
25. Kunig AM, Balasubramaniam V, Markham NE, Morgan D, Montgomery G, Grover TR, Abman SH. Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. Am J Physiol Lung Cell Mol Physiol 289: L529-L535, 2005.
26. Kunig AM, Balasubramaniam V, Markham NE, Seedorf G, Gien J, Abman SH. Recombinant human VEGF treatment transiently increases lung edema but enhances lung structure after neonatal hyperoxia. Am J Physiol Lung Cell Mol Physiol 291: L1068-L1078, 2006.
27. Lassus P, Heikkila P, Andersson LC, von Boguslawski K, Andersson S. Lower concentration of pulmonary hepatocyte growth factor is associated with more severe lung disease in preterm infants. J Pediatr 143: 199-202, 2003.
28. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 283: L555-L562, 2002.
29. Lin YJ, Markham NE, Balasubramaniam V, Tang JR, Maxey A, Kinsella JP, Abman SH. Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr Res 58: 22-29, 2005.
30. 2+-and phosphoinositide 3-kinase/Akt-dependent phosphorylation in aortic endothelial cells. Biochem J 374: 63-69, 2003.
31. McCurnin DC, Pierce RA, Chang LY, Gibson LL, Osborne-Lawrence S, Yoder BA, Kerecman JD, Albertine KH, Winter VT, Coalson JJ, Crapo JD, Grubb PH, Shaul PW. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am J Physiol Lung Cell Mol Physiol 288: L450-L459, 2005.
32. Meng F, Meliton A, Moldobaeva N, Mutlu G, Kawasaki Y, Akiyama T, Birukova A. Asef mediates HGF protective effects against LPSinduced lung injury and endothelial barrier dysfunction. Am J Physiol Lung Cell Mol Physiol 308: L452-L463, 2015.
33. Mercier JC, Hummler H, Durrmeyer X, Sanchez-Luna M, Carneielli V, Field D, Greenough A, Van Overmeire B, Jonsson B, Hallman M, Baldassarre J; EUNO Study Group. Inhaled nitric oxide for prevention of bronchopulmonary dysplasia in premature babies (EUNO): a randomised controlled trial. Lancet 376: 346-354, 2010.
34. Morrisey EE, Hogan BL. Preparing for the first breath: genetic and cellular mechanisms in lung development. Dev Cell 18: 8-23, 2010.
35. Muehlethaler V, Kunig AM, Seedorf G, Balasubramaniam V, Abman SH. Impaired VEGF and nitric oxide signaling after nitrofen exposure in rat fetal lung explants. Am J Physiol Lung Cell Mol Physiol 294: L110-L120, 2008.
36. Nakabayashi M, Morishita R, Nakagami H, Kuba K, Matsumoto K, Nakamura T, Tano Y, Kaneda Y. HGF/NK4 inhibited VEGF-induced angiogenesis in in vitro cultured endothelial cells and in vivo rabbit model. Diabetologia 46: 115-123, 2003.
37. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 276: 357-368, 1967.
38. Ohki Y, Mayuzumi H, Tokuyama K, Yoshizawa Y, Arakawa H, Mochizuki H, Morikawa A. Hepatocyte growth factor treatment improves alveolarization in a newborn murine model of bronchopulmonary dysplasia. Neonatology 95: 332-338, 2009.
39. Ohmichi H, Koshimizu U, Matsumoto K, Nakamura T. Hepatocyte growth factor (HGF) acts as a mesenchyme-derived morphogenic factor during fetal lung development. Development 125: 1315-1324, 1998.
40. Ohmichi H, Matsumoto K, Nakamura T. In vivo mitogenic action of HGF on lung epithelial cells: pulmotrophic role in lung regeneration. Am J Physiol Lung Cell Mol Physiol 270: L1031-L1039, 1996.
41. Okada M, Sugita K, Inukai T, Goi K, Kagami K, Kawasaki K, Nakazawa S. Hepatocyte growth factor protects small airway epithelial cells from apoptosis induced by tumor necrosis factor-alpha or oxidative stress. Pediatr Res 56: 336-344, 2004.
42. Ono M, Sawa Y, Matsumoto K, Nakamura T, Kaneda Y, Matsuda H. In vivo gene transfection with hepatocyte growth factor via the pulmonary artery induces angiogenesis in the rat lung. Circulation 106: I264-I269, 2002.
43. Panos RJ, Rubin JS, Csaky KG, Aaronson SA, Mason RJ. Keratinocyte growth factor and hepatocyte growth factor/scatter factor are heparinbinding growth factors for alveolar type II cells in fibroblast-conditioned medium. J Clin Invest 92: 969-977, 1993.
44. Raoul W, Chailley-Heu B, Barlier-Mur AM, Delacourt C, Maître B, Bourbon JR. Effects of vascular endothelial growth factor on isolated fetal alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 286: L1293-L1301, 2004.
45. Sengupta S, Sellers LA, Gherardi E, Sasisekharan R, Fan TP. Nitric oxide modulates hepatocyte growth factor/scatter factor-induced angiogenesis. Angiogenesis 7: 285-294, 2004.
46. Shannon J, Deterding R. Epithelial-mesenchymal interactions in lung development. In: Lung Growth and Development, edited by McDonald JA. New York: Dekker, 1997, p. 88-118.
47. Shannon JM, Pan T, Nielsen LD, Edeen KE, Mason RJ. Lung fibroblasts improve differentiation of rat type II cells in primary culture. Am J Respir Cell Mol Biol 24: 235-244, 2001.
48. Shigemura N, Sawa Y, Mizuno S, Ono M, Minami M, Okumura M, Nakamura T, Kaneda Y, Matsuda H. Induction of compensatory lung growth in pulmonary emphysema improves surgical outcomes in rats. Am J Respir Crit Care Med 171: 1237-1245, 2005.
49. Sonnenberg E, Meyer D, Weidner KM, Birchmeier C. Scatter factor/ hepatocyte growth factor and its receptor, the c-Met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol 123: 223-235, 1993.
50. Stenmark KR, Abman SH. Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 67: 623-661, 2005.
51. Stoll BJ, Hansen NI, Bell EF, Walsh MC, Carlo WA, Shankaran S, Laptook AR, Sánchez PJ, Van Meurs KP, Wyckoff M, Das A, Hale EC, Bethany Ball M, Newman NS, Schibler K, Poindexter BB, Kennedy KA, Cotten CM, Watterberg KL, D’Angio CT, DeMauro SB, Truog WE, Devaskar U, Higgins RD. Trends in care practices, morbidity, and mortality of extremely preterm Neonates, 1993-2012. JAMA 314: 1039-1051, 2015.
52. Tang JR, Seedorf G, Balasubramaniam V, Maxey A, Markham N, Abman SH. Early inhaled nitric oxide treatment decreases apoptosis of endothelial cells in neonatal rat lungs after vascular endothelial growth factor inhibition. Am J Physiol Lung Cell Mol Physiol 293: L1271-L1280, 2007.
53. Tang JR, Markham NE, Lin YJ, McMurtry IF, Maxey A, Kinsella JP, Abman SH. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol 287: L344-L351, 2004.
54. Thebaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, Eaton F, Hashimoto K, Harry G, Haromy A, Korbutt G, Archer SL. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxiainduced lung injury: evidence that angiogenesis participates in alveolarization. Circulation 112: 2477-2486, 2005.
55. Tourneux P, Markham N, Seedorf G, Balasubramaniam V, Abman S. Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin-induced bronchopulmonary dysplasia in neonatal rats. Am J Physiol Lung Cell Mol Physiol 297: L1103-L1111, 2009.
56. Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 290: L209-L221, 2006.
57. Wang Y, Crisostomo PR, Wang M, Weil B, Abarbanell A, Poynter J, Manukyan MC, Meldrum DR. Nitric oxide suppresses the secretion of vascular endothelial growth factor and hepatocyte growth factor from human mesenchymal stem cells. Shock 30: 527-531, 2008.
58. Wu S, Peng J, Duncan MR, Kasisomayajula K, Grotendorst G, Bancalari E. ALK-5 mediates endogenous and TGF-beta1-induced expression of connective tissue growth factor in embryonic lung. Am J Respir Cell Mol Biol 36: 552-561, 2007.
59. Yamamoto H, Yun EJ, Gerber HP, Ferrara N, Whitsett JA, Vu TH. Epithelial-vascular cross talk mediated by VEGF-A and HGF signaling directs primary septae formation during distal lung morphogenesis. Dev Biol 308: 44-53, 2007.